The FDA on March 22, 2023, granted accelerated approval to ZYNYZ® for adult patients with metastatic or recurrent locally advanced Merkel Cell Carcinoma (MCC). ZYNYZ® is a product of Incyte Corporation.
Other Pages – Bottom Ad
Advertisement
Subscribe
